|
|
|
|
|
|
By Uche Iloeje, MD, SpringWorks Therapeutics, Eileen K. Sawyer, Ph.D., SwanBio Therapeutics, John Yee, MD, MPH, Sobi North America, and J. Ross Maclean, MD, Precision Value & Health | When is the right time to engage medical affairs? If you're not sure when MA should make its debut, consider these 11 unique medical affairs contributions that should begin in discovery, be directly connected to other cross-functional deliverables, and continue through launch to support a successful R&D program. |
|
|
|
| Are Drugs Becoming More Lipophilic Over Time? | Article | By Jamie Unwin and Christian Jones, Nanoform | Get a deeper look into how drug lipophilicity has evolved over time, its impact on drug development, and the need for new technology to enable new, more complex drugs. |
|
|
| Reducing Wastewater Incineration And Carbon Emissions | Article | By Dr. Niklaus Künzle, and Dr. Andreas Sieber, Lonza | To reduce CO2 emissions and recycle higher volumes of solvent, drug manufacturers must engineer specialized approaches with flexible technologies that can be adapted to accommodate different products. |
|
|
|
|
| DPI Formulation Development And Manufacturing | Brochure | Lonza | The respiratory system provides an attractive drug-absorption target to treat local and systemic diseases and is increasingly used to deliver small molecules and biotherapeutics. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIFE SCIENCE LEADER MAGAZINE |
|
|
|
Have you heard of Life Science Leader? Check it out today for access to candid interviews with top-tier executives on how they do business. |
|
|